Zymeworks Inc. (NASDAQ:ZYME) Receives $33.00 Average PT from Analysts

by · The Cerbat Gem

Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) has earned an average recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, one has given a buy recommendation and four have given a strong buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $33.00.

Several equities research analysts have recently weighed in on ZYME shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a research report on Wednesday, October 8th. Zacks Research downgraded Zymeworks from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Truist Financial raised Zymeworks to a “strong-buy” rating in a report on Wednesday, December 17th. Citizens Jmp raised Zymeworks to a “strong-buy” rating in a report on Wednesday, December 3rd. Finally, Wall Street Zen lowered Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th.

Check Out Our Latest Analysis on Zymeworks

Zymeworks Stock Performance

Zymeworks stock opened at $27.23 on Friday. Zymeworks has a 52 week low of $9.03 and a 52 week high of $28.49. The stock has a market cap of $2.04 billion, a PE ratio of -32.42 and a beta of 1.27. The firm’s 50 day simple moving average is $22.00.

Zymeworks (NASDAQ:ZYME – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. Zymeworks had a negative net margin of 47.16% and a negative return on equity of 19.25%. The business had revenue of $27.61 million during the quarter, compared to analyst estimates of $28.27 million.

About Zymeworks

(Get Free Report)

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.

Featured Stories